title: Comparative effects of PACAP and VIP on pancreatic endocrine secretions and vascular resistance in rat.
abstract: 1. The effects of pituitary adenylate cyclase-activating polypeptide (PACAP), vasoactive intestinal peptide (VIP) and secretin on pancreatic endocrine secretions and vascular resistance were investigated and compared in the isolated perfused pancreas of the rat. The PACAP/VIP receptor types involved have been characterized. 2. On insulin secretion, in the range 10(-11) to 10(-8) M, PACAP and VIP elicited a concentration-dependent biphasic response from pancreas perfused with 8.3 mM glucose; the peptides were equipotent. In contrast, secretin was ineffective in the range 10(-11) to 10(-9) M; at 10(-8) and 10(-7) M, it induced only low and transient insulin responses. On the other hand, the peptides did not modify the basal insulin release in the presence of a non stimulating glucose concentration (2.8 mM). 3. On glucagon secretion, PACAP and VIP (10(-11) to 10(-8) M) but also secretin (10(-9) to 10(-7) M) caused a concentration-dependent peak shaped response from pancreas perfused with 2.8 mM glucose; PACAP and VIP were equipotent and 20 times more potent then secretin. On the other hand, the peptides did not affect the glucagon release in the presence of 8.3 mM glucose. 4. On pancreatic vessels, in the range 10(-11) to 10(-9) M, the three peptides were equipotent in inducing a concentration-dependent sustained increase in pancreatic flow rate. On the other hand, at the high concentration of 10(-7) M PACAP but not VIP provoked a transient decrease of flow rate. 5. This study provides evidence for PACAP/VIP type II receptors mediating insulin and glucagon secretion as well as vasodilatation in rat pancreas. In addition, the different efficacies of secretin suggest that these effects are mediated by different PACAP/VIP type II receptor subtypes.
authors.affiliation: Centre CNRS-INSERM de Pharmacologie Endocrinologie, UPR 9023, Montepellier, France.
authors.forename: G
authors.initials: G
authors.lastname: Bertrand
authors.forename: R
authors.initials: R
authors.lastname: Puech
authors.forename: Y
authors.initials: Y
authors.lastname: Maisonnasse
authors.forename: J
authors.initials: J
authors.lastname: Bockaert
authors.forename: M M
authors.initials: MM
authors.lastname: Loubatières-Mariani
mesh_terms: D000818:Animals; D005934:Glucagon / Q000378:metabolism; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D008297:Male; D009479:Neuropeptides / Q000494:pharmacology*; D010179:Pancreas / Q000187:drug effects* / Q000378:metabolism; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D051381:Rats; D017208:Rats, Wistar; D012633:Secretin / Q000378:metabolism; D014655:Vascular Resistance / Q000187:drug effects*; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology*
chemical_list: C495403:Adcyap1 protein, rat; D007328:Insulin; D009479:Neuropeptides; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D012633:Secretin; D014660:Vasoactive Intestinal Peptide; D005934:Glucagon